


Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations



For Private Circulation Only

## Editorial

Through the latest Patents (Amendment) Rules, 2021, the Government of India has extended 80% reduction in patent filing and prosecution to all Educational Institutions.

The Draft Patents (Amendment) Rules, 2021 published in Gazette of India on 9th February, 2021 defined 'eligible educational institution' as *"an institution established by a Central, Provincial or State Act, which is owned or controlled by the Government, and is wholly or substantially financed by the Government"*. Subsequently in August 2021, the Commerce and Industry Minister Hon'ble Mr. Piyush Goyal announced that 80% fee reduction will apply to all recognized educational institutions whether it is government (owned), government-aided, or private institutions. Accordingly, on 21st September 2021, Minister of Commerce and Industry notified Patents (Amendment) Rules, 2021, wherein 'eligible educational institution' is now defined as *"university established or incorporated by or under Central Act, a Provincial Act, or a State Act, and includes any other educational institution as recognised by an authority designated by the Central Government or the State Government or the Union territories in this regard;"*

Link to the relevant notification:

[https://ipindia.gov.in/writereaddata/Portal/News/758\\_1\\_Patents\\_Amendment\\_Rules\\_2021.pdf](https://ipindia.gov.in/writereaddata/Portal/News/758_1_Patents_Amendment_Rules_2021.pdf)

## Webinar Invitation

28th October, 2021

Thursday, 4:00 to 5:00 PM

### FUN LEARNINGS OF IP & TECHNOLOGY LAW -with Anecdotes



Patent Gurukul in association with CIPROM & GNANLex Associates LLP presents webinar



Speaker - Dr. Gopakumar G. Nair

FREE REGISTRATION

Contact us - [ipr@gnanlex.net](mailto:ipr@gnanlex.net), [gopanair@gnaipr.net](mailto:gopanair@gnaipr.net)

Click on:

[https://docs.google.com/forms/d/e/1FAIpQLSdfMk32pycmtAkL7WP0mQm\\_sabidhyh405r2Yolt01k-q5u6w/viewform?usp=sf\\_link](https://docs.google.com/forms/d/e/1FAIpQLSdfMk32pycmtAkL7WP0mQm_sabidhyh405r2Yolt01k-q5u6w/viewform?usp=sf_link)

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations

**For Private Circulation Only**

## **Sirmaxo Launches New Division “Pharmasurance” on upbeat note!**

New vertical dedicated to Pharma Industry is an offshoot of increasing demand from Compliance sections for effective validated solutions in disinfection. Sirmaxo, being a pioneer in India since 1978, accepted responsibility to lead from the front.

Pharma Division Launch was presided over by doyen of Pharma World, Mr Davinder Singh Sir on 25<sup>th</sup> August, 2021 at Mumbai Headquarters of Sirmaxo Chemicals Pvt Ltd. Mr Pramod Lele, ex MD-Johnson & Johnson convened the event with Board members, Chairman Suresh ji Bhatwadekar, Vice Chairperson – Hema Bhatwadekar, Managing Director – Jaydeep Bhatwadekar & Technical Director- Kalpana Bhatwadekar. Complete details available on social media handles.

Sirmaxo Chemicals pledges to closely partner with leading Pharma Giants in providing complete control over disinfectants action for Safety of Patients, Operators, Processes, Product & Facility. Sirmaxo has a strong base of WHO-GMP, ISO 9001: 2015, ISO 13485: 2016 accredited state of the art facility backed by innovative R & D pipeline (under approval of DSIR). Company has reserved its spare capacity from an annual installed strength of 10 million liters per shift from both its Plants in MIDC, Boisar. Manufacturing area of class ‘D’ is a unique advantage for controlled environment Product expectations. Products efficacy are tested at Multination Labs on 16 critical surfaces prevalent in manufacturing Units, successfully.

Sirmaxo is already on Rate Contract, Approved Vendor list of Cipla & number of listed Pharma Giants for more than a decade with a proven record of uninterrupted supplies. Customer service is a top most priority. Products are EN certified by external & international Agencies, meeting Pharmacopoeial standards. Few Products are CE certified. Exports are mainly to Central America, Latam, Europe, CIS, Asia, Middle East & Africa followed by registrations at many more markets.

Sirmaxo is a technologically advanced manufacturing Company offering one-stop professional solutions / hygiene control that covers broad categories viz. Hand Hygiene, Skin Antiseptics, Instrument Disinfectants, Surface Disinfectants & Oral Hygiene. Sirmaxo has lined up 7 specialty Products for Pharma applications & few more under development:

- 1) Saniscrub M: Safe & effective handrub
- 2) Sanihigene: Multipurpose surface disinfectant
- 3) Saniocid: Low alcohol concentrate spray disinfectant
- 4) Sanillocid SP: Aldehyde based surface disinfectant
- 5) Sanishield: Sporicidal surface disinfectant
- 6) Saniocid RF: Spray disinfectant for high touch surfaces
- 7) Saniquad 40 P: Surface disinfectant for general area

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations

**For Private Circulation Only**

Inhouse R & D facilitates advancement in new formulations equipped with Microbiology Labs of nextgen. Social media is abuzz with praises & interesting enquiries for collaborative solutions in disinfectants.

Sirmaxo is committed to support its Partners in Regulatory compliance, documentation, validation, method development & work together on any challenges.



## **You are testing our patience: SC raps Centre over delay in Tribunal appointments**

The Supreme Court rapped the central government on Monday over the delay in appointments to the Tribunals, saying the "you are testing our patience". The court also said that the provisions in the Tribunals Reforms Act were identical to the ones it struck down earlier. A special bench headed by Chief Justice of India NV Ramana and comprising Justices DY Chandrachud and L Nageswara Rao directed the government to appoint members/chairs of various Tribunals. The court asked the government to appoint the names recommended in the last two years before the Tribunals Reforms Act came.

Source: <https://www.indiatoday.in/law/story/supreme-court-raps-centre-delay-tribunal-appointments-1849684-2021-09-06>

## **AI cannot be the inventor of a patent, appeals court rules**

Artificial intelligence (AI) cannot be the inventor of new patents, the UK Court of Appeal has ruled. Patents assign the ownership of a new invention to its creator. The appeal court ruled against Stephen Thaler, creator of a system called Dabus, who took a case against the UK's Intellectual Property Office (IPO) which refused patents to his AI.

Source: <https://www.bbc.com/news/technology-58668534>

Intellectual Property advocacy in the fields of:

- IP Infrastructure
- IP Valuation
- M & A
- IP Policy
- Technology Transfer
- Innovation Research
- Patent Law
- Licensing
- Data Management
- Copyright
- Collaborations
- Balance for Rights & Obligations



For Private Circulation Only

## Emami gets edge in trademark case against Dr. Morepen

FMCG major Emami on 13<sup>th</sup> September 2021 has a favorable order on a trademark infringement suit against Dr. Morepen a leading pharma organization. Emami had claimed that it is the enrolled proprietor of word “Pancharishta” since 1968 and furthermore the enlisted owner of the mark “Zandu Pancharishta” and “Zandu Pancharishta Plus” other than different registrations of the said mark “Pancharishta” the two words and labels mark and the company professed to be the primary client of the said mark. The defendant explained that the word “Pancharishta” is based on traditional ayurvedic texts. “Arishta” has been described as a drug which is prepared using water and boiling the same is scripted in Sarngadhara-Samhita, published from Varanasi. The defendant claimed that as “Arishta” is an ayurvedic preparation, so no monopoly can be claimed or granted in respect of the same.



Source: <https://ipjagruti.com/2021/09/15/emami-gets-edge-in-trademark-case-against-dr-morepen/>

## Mondelez threatens trademark battle over bar's lilac packaging

A multinational confectionery company has threatened legal action against a London vegan snack maker over the colour of one of its fruit bars. Mondelez alleges that Primal Pantry's cocoa bar "exploits" the trademark of its Milka chocolate range. Lawyers for Mondelez are demanding the use of lilac packaging for the bar must stop, warning of a £5,200 penalty each time the trademark is infringed.



Source: <https://www.bbc.com/news/uk-england-london-58642113>

## Hardlook: Copyright vs wrong — the Sci-Hub case being fought in Delhi

A case between three academic publishers and the creator of pirate website Sci-Hub is currently being fought in the Delhi High Court.

In December 2020, three major academic publishers — Elsevier, Wiley, and American Chemical Society — moved the court against Kazakh computer programmer Alexandra Elbakyan and website LibGen and its related additional domains. Elbakyan is the creator and owner of Sci-Hub, a pirate website which enables users to download research papers for free, bypassing paywalls and restrictions.

Source: <https://indianexpress.com/article/cities/delhi/delhi-high-court-academicians-scientists-researchers-7536252/>